REFERENCIAS (Tiroidectomia Total)

1. Cady B. Our AMES is true: how an old concept still hits the mark—or, risk group assignment points the arrow to rational therapy selection in differentiated. thyroid cancer. Am J Surg. 1997;174:462– 8.

2. Shaha AR, Loree TR, Shah JP. 1995 Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery. 1995;118:1131–8.

3. Benninger MS, Guillen JB, Altman JS. Changing etiology of vocal fold immobility. Laryngoscope 1998;108;1346-50

4. Havas T, Lowinger D, Priestley J. Unilateral vocal fold paralysis: causes, options and outcomes. Austr N Z J Surg 1999;69:509-13

5. Fewins J, Simpson B, Miller FR. Complications of thyroid and parathyroid surgery. Otolaryngologic Clinics of North America 2003;36

6. Udelsman R, Lakatos E, Ladenson P. Optimal surgery for papillary thyroid carcinoma. World J Surg 1996;20:88-93

7. Koyunku A, Dokmetas HS, Turan M, Aydin C,Karayadi K, Budak E, et al. Comparison of different thyroidectomy techniques for benign thyroid disease. Endocrine Journal 2003;50:723-7

8. Rosato L, Avenia N, Bernante P, De Palma M, Gulino G, Nasi PG, Pelizzo MR, Pezzullo Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J Surg. 2004;28:271

9. Filho JG, Kowalski LP. Postoperative complications of thyroidectomy for differentiated thyroid carcinoma. Am J Otolaryngol. 2004;25:225-30.

10. Kupferman ME, Mandel SJ, DiDonato L, Wolf P, Weber RS. Safety of completion thyroidectomy following unilateral lobectomy for well-differentiated thyroid cancer. Laryngoscope. 2002;112:1209-12.

11. Bhattacharyya N, Fried MP. Assessment of the morbidity and complications of total thyroidectomy. Arch Otolaryngol Head Neck Surg. 2002;128:389-92.

12. Gough IR, Wilkinson D. Total thyroidectomy for management of thyroid disease. World J Surg 2000;24:962-5

13. Clark OH. Total thyroidectomy: the treatment of choice for patients with differentiated thyroid cancer. An Surg 1982;196:361-70

14. Rodríguez CS, Labastida AS, Olano NO, Muñoz CML. Morbilidad debida a tiroidectomía por cáncer. Cir Gen 1996;18:92-97

15. Hurtado-Lopez LM, Pulido-Cejudo A, Basurto-Kuba E. Puntos clave para una adecuada y segura identificación del nervio laringeo recurrente durante la tiroidectomía. Aplicación en 100 tiroidectomías. Cir Gen 1998;20:95-98

16. Hurtado-López LM, Pulido-cejudo A, Zaldivar-Ramirez FR, Basurto-Kuba E. A propósito de la localización del nervio laríngeo recurrente y las glándulas paratiroides inferior en la cirugía de tiroides. Como lo hago yo. Cir Gen 2000;22(3):283-286.

17. Pulido Cejudo A, Hurtado-López LM, Basurto Kuba E, Cárdenas del Olmo A, Muñoz Solís O, Zaldívar Ramírez FR, Gómez Arciniega M, Rangel Cruz ESH. Sistematización de la técnica de tiroidectomía y su impacto en la morbilidad Cir Gen. 2004;26:286-9

18. Hurtado-López LM, Zaldivar-Ramirez FR, Basurto-Kuba E, Pulido-cejudo A, Muñoz-Solis O, Cardenas-Del Olmo A. La morbilidad no limita la extensión quirurgica del cancer diferenciado de tiroides. Cir Gen 2003;25 (supl 1):s9-s10

19. Pasieka JL, Rotstein LE. Consensus conference on well-differentiated thyroid cancer: a summary. Can J Surg. 1993;36:298-301

20. Cernea CR, Ferraz AR, Nishio S, Dutra A, Hojaji F, et al. Surgical anatomy of the external branch of the superior laryngeal nerve. Head & Neck 1992;14:380-383.

21. Hurtado López LM, Zaldívar RF. 2002 Risk of injury to the external branch of the superior laryngeal nerve in thyroidectomy. Laryngoscope 112:626-629.

22. Cernea CR, Ferraz AR, Furlani J, Monteiro S, Nishio S, et al. 1992 Identification of the external branch of the superior laryngeal nerve during thyroidectomy. Am J Surg 164:634-639.

23. Hurtado López LM, Pacheco-Alvarez M I, Montes-Castillo M D L, Zaldivar-Ramirez F-R. Importance of the intraoperative identification of the external branch of the superior laryngeal nerve during thyroidectomy. electromyographic evaluation. Thyroid (en prensa)

24. Madrid Franco JR, Lozano López I. Enfermedad quirúrgica no traumática del cuello ¿estoy preparado para enfrentarla? Cir Gen 2004;26:155-7

25. Sosa, JA, et al. The Importance of Surgeon Experience for Clinical and Economic Outcomes From Thyroidectomy: Annals of Surgery; 1998, 228:320-30

26. Baucourt F, Asselain B, Savie JC. Multifactorial study of prognostic factors in diffentiated thyroid carcinoma and a re-evaluation of the importance of age. Br J Surg 1986;73:274-77

27. McConahey WM, Hay ID, Woolner LB, Van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo clinic, 1946 through 1970: inicial manifestations athologic findings, therpy and outcome. Mayo Clin Proc 1986;61:978-96.

28. Avenia N, Ragusa M, Monacelli M, Calzolari F, Daddi N, Di Carlo L, Semeraro A, Puma F. Locally advanced thyroid cancer: therapeutic options. Chir Ital. 2004;56:501-8.

29. Marchesi M, Biffoni M, Biancari F, Berni A, Campana FP. Predictors of outcome for patients with differentiated and aggressive thyroid carcinoma. Eur J Surg Suppl. 2003;588:46-50

30. Kitamura Y, Shimizu K, Nagahama M, et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab. 1999;84:4043– 4049.

31. Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore). 1977;56:171-96.

32. Byar DP, Green SB, Dor P. A prognostic index for thyroid carcinoma: a study of the EORTC thyroid cancer cooperative group. Eur J cancer 1979;15:1033-41

33. Simpson WJ, McKinney S. Canadian survey of thyroid cancer. Can Med Assoc J 1985;132:925-31

34. Simpson WJ, McKinney S, Carruthers JS, Gospodarowics MK, Papillary and follicular thyroid cancer. Prognostic factors in 1578 patients. Am J Med 1987;83:479-88

35. Hay ID, Grant CS, Taylor WF. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: A retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088-95

36. Cady B, Rossi R. An expanded view of risk group definition in difefereniated thyroid carcinoma. Surgery 1988; 104:947-53

37. Hay ID, Bergstralh EJ, Goellner JR. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system is a cohort of 1779 paients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050-58

38. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment and course of papillary carcinoma J Clin Endocrinol Metab 1990;71:414-24

39. Shaha AR, Loree TR, Shah JP, Prognostic factors and risk group analysis in follicular carcinoma ot the thyroid. Surgery 1995;118:1131-38

40. Sherman SI, Brierley JD, Sperling M. Prospective multicenter study of thyroid carcinoma treatment. Initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative study registry group. Cancer 1998;83:1012-21

41. Mazzaferri EL.1999 NCCN thyroid carcinoma practice guidelines. Oncology 13(11A, NCCN proceedings):391-442

42. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T, Ito K, Ito K, Tanaka S. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab. 1999;84:4043-9.

43. Rodriguez Cuevas SA, Labastida AS, Rodríguez ME, Reyas CJM. Papillary carcinoma in Mexico: análisis of 409 cases. Head Neck 1993;15:537-45

44. Herrera MF, Lopez-Graniel CM, Saldaña J, Gamboa-Dominguez A, Richaud-Patin Y, VargasVorackova F, et al. Papillary thyroid carcinoma in Mexican patients: clinical aspects and prognostica factors World J Surg 1996;20:94-100

45. Mazzaferri EL , Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocrine-Related cancer 2002;9:227

46. Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J surg 1994;18:559

47. Beasley NJ, Lee J, Eski S, Walfish P, Witterck I, Freeman JL. Impact of nodal metastasis on prognosis in patients with well-differentiated thyroid cancer. Arch Oyolaryngol Head Neck Surg 2002;128:825

48. Clark OH. Total thyroidectomy: the treatment of choice for patients with differentiated thyroid cancer. Ann Surg 1982;196:361-70

49. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med. 1988;29:1790-4.

50. Dackiw AP, Zeiger M. Extent of surgery for differentiated thyroid cancer Surg Clin North Am 2004;84: 817-32

51. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc. 1986;61:978-96.

52. Massin JP, Savoie JC, Garnier H, Guiraudon G, Leger FA, Bacourt F. Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment.Cancer. 1984;53:982-92.

53. Mishra A, Mishra SK, Agarwal A, Das BK, Agarwal G, Gambhir S. Metastatic differentiated thyroid carcinoma: clinicopathological profile and outcome in an iodine deficient area. World J Surg. 2002;26:153-7.

54. Pacini F, Cetani F, Miccoli P, Mancusi F, Ceccarelli C, Lippi F, Martino E, Pinchera A. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg. 1994;18:600-4.

55. Zohar Y, Strauss M. Occult distant metastases of well-differentiated thyroid carcinoma. Head Neck.1994;16:438-42.

56. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-63

57. Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner JR. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998;124:958-64.

58. DeGroot LJ, Kaplan EL, Straus FH, Shukla MS. Does the method of management of papillary thyroid carcinoma make a difference in outcome? World J Surg 1994;18:123-30.

59. Cushing SL, Palme CE, Audet N, Eski S, Walfish PG, Freeman JL. Prognostic Factors in Well-Differentiated Thyroid Carcinoma. Laryngoscope. 2004;114:2110-15.

60. Orsenigo E, Beretta E, Fiacco E, Scaltrini F, Veronesi P, Invernizzi L, Gini P, Fiorina P, Di Carlo V.Management of papillary microcarcinoma of the thyroid gland. Eur J Surg Oncol. 2004 Dec;30(10):1104-6. Orsenigo E, Beretta E, Fiacco E, Scaltrini F, Veronesi P, Invernizzi L, Gini P, Fiorina P, Di Carlo V.Management of papillary microcarcinoma of the thyroid gland. Eur J Surg Oncol. 2004;30:1104-6.

61. Kim S, Wei JP, Braveman JM, Brams DM. Predicting outcome and directing therapy for papillary thyroid carcinoma. Arch Surg. 2004;139:390-4.

62. Ashok R. Shaha, Implications of Prognostic Factors and Risk Groups in the Management of Differentiated Thyroid Cancer Laryngoscope,2004;114:393–402.

63. Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol. 2004;22:3531-9.

64. Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab. 2004;89:3713-20

65. Spitzweg C, Morris JC. Gene therapy for thyroid cancer: Current status and future prospects. Thyroid 2004;14:424-34
Principal | Quién es Dr. Hurtado | Glándulas Tiroides | Preguntas Frecuentes | Pregúnteme | Mapa